TEMODAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623868 | MERCK SHARP DOHME | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(7 months ago) | |
| US7786118 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(7 months ago) | |
| US6987108 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep, 2023
(16 days ago) | |
Temodar is owned by Merck Sharp Dohme.
Temodar contains Temozolomide.
Temodar has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Temodar are:
- US8623868
- US7786118
- US6987108
Temodar was authorised for market use on 27 February, 2009.
Temodar is available in powder;intravenous dosage forms.
The generics of Temodar are possible to be released after 08 September, 2023.
Drugs and Companies using TEMOZOLOMIDE ingredient
Market Authorisation Date: 27 February, 2009
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
TEMODAR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic